BioNTech Total Other Income Expense Net yearly trend continues to be quite stable with very little volatility. Total Other Income Expense Net may rise above about -64.4 M this year. From the period between 2010 and 2024, BioNTech, Total Other Income Expense Net regression line of its data series had sample variance of 28361 T and sample variance of 28361 T. View All Fundamentals
Total Other Income Expense Net
First Reported
2010-12-31
Previous Quarter
-67.8 M
Current Value
-64.4 M
Quarterly Volatility
168.4 M
Credit Downgrade
Yuan Drop
Covid
Check BioNTech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BioNTech's main balance sheet or income statement drivers, such as Interest Expense of 5.3 M, Other Operating Expenses of 385.3 M or EBIT of 14.4 B, as well as many indicators such as . BioNTech financial statements analysis is a perfect complement when working with BioNTech Valuation or Volatility modules.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
When determining whether BioNTech SE offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BioNTech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biontech Se Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biontech Se Stock:
Please note, there is a significant difference between BioNTech's value and its price as these two are different measures arrived at by different means. Investors typically determine if BioNTech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioNTech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.